Director Susan Altschuller buys 10.0K shares of MURA at $3.21; stock down -47.6% from 52-week high, company unprofitable ($-31.6M net income).
Susan Altschuller, a director, made an open-market purchase of 10,000 shares at $3.21 on 2024-08-14, establishing a new position in Mural Oncology. The timing occurs against a backdrop of significant stock weakness: the stock is -47.6% from its 52-week high of $6.01 and has declined -8.7% over the prior 30 days and -16.2% over 90 days. Fundamentally, the company reported negative net income of $-31,564,000.00 over its most recent full fiscal year, reflecting material profitability challenges. Across Altschuller's prior open-market history across all tickers, her historical trade execution shows limited timing accuracy: a 0.00% well-timed rate on 1 prior sell, suggesting her past sales have not coincided with subsequent stock declines.